SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as the community rallies around its fair launch and strong ties to the Bitcoin blockchain, touting it as the top meme coin in the Bitcoin ecosystem. Community members highlight its unique story, lack of insiders, and potential for significant growth, drawing comparisons to previous meme coin successes. The #DOGArmy is actively pushing for increased visibility and exchange listings.

Ainalyzr is a versatile and engaging platform designed to provide crypto traders with advanced tools and a fun, interactive environment. Powered by the Ainalyzr token, it offers real-time analysis of Solana-based tokens, gamified trading tools, and a space for users to explore market trends and make data-driven decisions. Ainalyzr merges functionality and entertainment, appealing to both seasoned and novice traders.

AInalyzr

AInalyzr ($AINAL.X) is gaining traction, with the community highlighting its potential for a significant surge, referring to it as a 'hidden gem' ready for 'liftoff'. Discussions emphasize early accumulation and strong holding, suggesting a belief in substantial future gains. The coin is associated with the Solana blockchain, as indicated by the multiple mentions of $SOL.X.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT.X) is trending as traders discuss its recent listing and potential for significant price movement, with some speculating about upcoming milestones. The community is weighing the risks and rewards, particularly in comparison to other new listings. Bullish investors are pointing to the project's fundamentals and potential for gains.

Decentraland

Decentraland is trending as the community discusses its potential for growth within the metaverse, speculating on upcoming catalysts and price targets. Some investors are optimistic about the long-term prospects of MANA.X and the metaverse sector, while others await a breakout above key resistance levels.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is trending as the community discusses its potential for tokenizing financial assets and the impact of broader market trends, including possible interest rate cuts.  Debate centers around Algorand's current price action, future potential, and the leadership of the Algorand Foundation. Some traders are pointing to bullish chart patterns, while others express concerns about transaction fees and historical performance relative to Bitcoin.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as community members rally around the project's mission to support dog shelters through charitable donations, highlighting the project's genuine efforts and ongoing donations. Many are drawn to its charitable aspect, with some seeing it as a promising project within the meme coin space on the Solana network. The community is actively spreading the word and expressing bullish sentiment.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amid heated discussions surrounding a recent shooting and its alleged connection to political figures, sparking debates about media narratives and violence. The community is actively engaged in pointing fingers and assigning blame, highlighting the deep divisions within the current political climate. Broader context includes ongoing debates about extremism and political rhetoric.

Teck Resources Limited is a resource company, which engages in the exploration, acquisition, development, production, and sale of natural resources. Its products include steelmaking coal, copper, zinc, industrial products and fertilizers, and other metals. Its project operations are located in Canada, Peru, U.S., and Chile. The company was founded on September 24, 1951 and is headquartered in Vancouver, Canada.

Teck Resources Ltd - Ordinary Shares - Class B (Sub Voting)

Teck Resources Ltd - Ordinary Shares - Class B

Teck Resources is trending due to its pending merger with Anglo American, a deal valued around $53B, which would create a global copper giant named Anglo Teck. Community discussions revolve around the deal's implications for copper supply, potential competing offers, and the overall valuation of Anglo Teck. Some analysts believe the combined entity is well-positioned to capitalize on the increasing demand for copper in the AI and electrification sectors.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community anticipates potential catalysts and debates possible price targets, with some highlighting upcoming events and others calling for continued holding. Community members are actively discussing Dogecoin's potential in the broader crypto market, comparing it to other meme coins, and watching for key resistance levels. Some users cite news related to Elon Musk's lawyer preparing a treasury company focused on Dogecoin as a catalyst.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community discusses its potential for continued growth and adoption, fueled by institutional interest and treasury investments. A topic of conversation centers around meme coins built on Solana's blockchain.  Some traders are pointing to key resistance levels and anticipating a breakout soon.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of&nbsp;micro-cap Quantum Corp. (QMCO) declined sharply in the after-hours session on Wednesday following its disappointing quarterly results.<a href="https://stocktwits.com/symbol/QMCO">Quantum stock</a> ended the after-hours session down 15.40% but has since then trimmed some of the losses in overnight trading.Retail users of Stocktwits have shrugged off the stock drop and remained ‘extremely bullish’ (92/100) as of late Wednesday, and the message volume improved to ‘extremely high.’ The 24-hour message volume change leading up to late Wednesday was over 500%.<figure class="image"><img style="aspect-ratio:618/49;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_10_at_10_12_07_PM_png_6bb215f787.webp" alt="Screenshot 2025-09-10 at 10.12.07 PM.png" width="618" height="49"><figcaption>QMCO sentiment and message volume as of 10:10 p.m. ET, Sept. 10 | source: Stocktwits</figcaption></figure>Quantum, a data management platform company, reported an adjusted loss per share of $1.58 for the first quarter of fiscal year 2026, slightly narrower than the $1.59 loss reported for the year-ago quarter.Revenue fell to $64.3 million from $72.3 million reported for the year-ago quarter. Analysts, on average, expected a loss per share of $0.43 and revenue of $70.7 million for the quarter, according to Fiscal.ai.The adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) widened to a negative $6.5 million from a negative $2.2 million last year. The company’s cash position improved to $37.5 million at the end of the quarter from $16.6 million at the end of the March quarter.Looking forward, Quantum guided to second-quarter revenue of $61 million, plus or minus $2 million, below the analysts’ consensus of $72.35 million. The company’s adjusted loss per share guidance is $0.26, plus or minus $0.10, compared to the analysts' $0.40 loss per share estimate. It aims to achieve breakeven EBITDA for the quarter.Hugues Meyrath, who assumed the CEO role at the company in June, said, “Leveraging extensive industry experience and my familiarity of the Company as a board member, the Company has implemented immediate and ongoing actions aimed at further improving the cost structure and balance sheet.”“Despite the disappointing performance in [the] fiscal first quarter, we are encouraged by positive developments and renewed business prospects following the refresh of our leadership team. We expect our decisive actions to result in noticeably improved bottom-line performance beginning in the September quarter.”Quantum stock is down about 85% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/toyota-reshapes-us-operations-under-tariff-pressure-ev-su-vs-coming-to-kentucky-lexus-es-shifts-to-japan/chwNbuKRdHb">Toyota Reshapes US Operations Under Tariff Pressure — EV SUVs Coming To Kentucky, Lexus ES Shifts To Japan</a>

In this photo illustration, the logo of Quantum Corporation is displayed on a smartphone screen with a blurred version of the company's branding in the background on June 27, 2025 in Chongqing, China. 

Why Quantum Corp. Stock Plunged In Today’s After-Hours

CEO Hugues Meyrath said the company’s decisive actions would result in noticeably improved bottom-line performance beginning in the September quarter.

Equity

CEO Hugues Meyrath said the company’s decisive actions would result in noticeably improved bottom-line performance beginning in the September quarter.


H.C. Wainwright on Monday set a price target of $11 for CervoMed (CRVO) shares while keeping a ‘Neutral’ rating. The target implies a premium of nearly 5% from the stock’s closing price on Friday.The regulatory outlook for Neflamapimod should be clarified in the near term, the analyst told investors in a research note. The firm noted CervoMed is actively preparing for discussions with the U.S. Food and Drug Administration (FDA), which management expects to take place during the fourth quarter.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CRVO">CervoMed</a> trended in the ‘extremely bullish’ territory, while message volume is at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_08_at_12_48_27_PM_png_0e348d0430.webp" alt="CRVO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Sept. 8, 2025 | Source: Stocktwits" width="576" height="63"><figcaption>CRVO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Sept. 8, 2025 | Source: Stocktwits</figcaption></figure>Late in July, Cervomed <a href="https://stocktwits.com/news-articles/markets/equity/cervomed-dementia-drug-slows-disease-progression-in-study/choeuj6R5xa">said</a> that Neflamapimod continued to slow disease progression in a type of dementia during the extension phase of its mid-stage trial. Dementia with Lewy Bodies (DLB) patients treated with Neflamapimod showed a 54% risk reduction in clinically significant worsening at week 32 of treatment, the company said.DLB is a type of dementia characterized by the presence of Lewy bodies, which are protein clumps, in the brain. It is the second most common form of neurodegenerative dementia, following Alzheimer's disease.The company then also confirmed that it is looking forward to initiating late-stage trials and is preparing to meet with the U.S. Food and Drug Administration in the fourth quarter to align on the trial design.In the second quarter of 2025, CervoMed also enrolled the first patients in a mid-stage trial of Neflamapimod in patients recovering from acute stroke. It also initiated a mid-stage trial of Neflamapimod in patients with the nonfluent/agrammatic variant of primary progressive aphasia (PPA) – a subtype of frontotemporal dementia (FTD).Neflamapimod was granted Orphan Drug designation for the treatment of FTD in November 2024. Frontotemporal dementia (FTD) is a group of brain disorders characterized by the progressive degeneration of the brain's frontal and temporal lobes, leading to changes in personality, behavior, and language.According to data from Koyfin, all six analysts covering CervoMed rate it a ‘Buy’. The stock has an average price target of $21.50.CRVO stock is up 334% this year but down approximately 36% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/stellantis-stock-slips-after-us-regulator-probes-287000-chrysler-minivans/chwhGZoRdrX">Stellantis Stock Slips After US Regulator Probes 287,000 Chrysler Minivans Over Concerns Regarding Electric Power Steer</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

CervoMed Gets $11 Price Target From HC Wainwright, Analyst Says Regulatory Outlook For Experimental Dementia Drug Should Be Clear Soon

H.C. Wainwright’s price target implies a premium of nearly 5% from the stock’s closing price on Friday.

CervoMed Gets $11 Price Target From HC Wainwright, Analyst Says Regulatory Outlook For Experimental Dementia Drug Should Be Clear Soon 

H.C. Wainwright’s price target implies a premium of nearly 5% from the stock’s closing price on Friday.


Nukkleus Inc. (NUKK) and Mandragola on Friday announced the establishment of a strategic joint venture focused on commercial and defense-oriented infrastructure modernization.Mandragola is an Israeli business development and investment company specializing in advanced technologies and strategic partnerships. The companies <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/29/3141492/0/en/Nukkleus-Inc-Expands-Aerospace-Defense-Footprint-with-Strategic-European-Joint-Venture.html">said</a> that they intend to establish advanced manufacturing zones in both the Baltics and Israel, designed to support civil and defense aviation needs, under the new venture.The companies also plan to develop a NATO-compliant logistics hub in Riga in cooperation with additional regional partners, as well as facilities dedicated to licensed aircraft Maintenance, Repair, and Overhaul (MRO) services, aircraft modernization, resale, and leasing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NUKK">Nukkleus</a> stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:578/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_29_at_11_00_51_AM_png_e21f0150af.webp" alt="NUKK's Sentiment Meter and Message Volume as of 11:01 a.m. ET on Aug. 29, 2025 | Source: Stocktwits" width="578" height="61"><figcaption>NUKK's Sentiment Meter and Message Volume as of 11:01 a.m. ET on Aug. 29, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that the stock is now tearing down walls set up by shorts.<stembedurl>https://stocktwits.com/Bfomo/message/627013481</stembedurl>Another user recommended buying and holding the shares.<stembedurl>https://stocktwits.com/Jumpinjackflash33/message/627013022</stembedurl>A five-member board of directors will lead the new venture along with an advisory board featuring aviation professionals, including two former Israeli Air Force pilots.The partnership will also aim to identify and finance early-stage technology companies in Israel that can be integrated into aviation and defense operations. The new venture will serve as the “cornerstone of Nukkleus’ European aviation and defense operations,” providing a strong foundation for future growth, the company said.The initiative comes at a time when ongoing geopolitical tensions continue to reshape regional defense priorities, the company noted, while adding that the global aircraft MRO market is projected to expand to $124 billion by 2034.NUKK stock is down by 86% this year, but has more than doubled in value over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/lucid-stock-gets-price-target-cut-from-stifel-as-it-gears-up-for-reverse-stock-split/chtTSAXRdNK">Lucid Stock Gets A Price Target Cut From Stifel As It Gears Up For A Reverse Stock Split: Retail Sees 50% Dive Post Split</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

Nukkleus Stock Shot Up A Whopping 37% Today – Here’s What Happened

Nukkleus and Mandragola stated they intend to establish advanced manufacturing zones in both the Baltics and Israel, designed to support civil and defense aviation needs, under a new venture. 

Outlook Therapeutics, Inc. (OTLK) announced on Thursday that the U.S. Food and Drug Administration (FDA) has declined to approve its investigational drug Lytenava for the treatment of wet age-related macular degeneration. Shares of the company nosedived by over 66% in Thursday’s pre-market session following the announcement.The agency cited a lack of substantial evidence of effectiveness as the basis for its decision. Age-related macular degeneration causes damage to the macula, a small area near the center of the retina, which is the part of the eye responsible for sharp, central vision. It is common among people aged 50 and older. Wet age-related macular degeneration (wet AMD) is an advanced form of AMD where abnormal, leaky blood vessels grow under the retina, leading to rapid vision loss.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OTLK">OTLK stock</a> trended within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.The agency <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/28/3140631/0/en/Outlook-Therapeutics-Provides-Regulatory-Update-on-U-S-Food-and-Drug-Administration-Review-of-ONS-5010-LYTENAVA-bevacizumab-vikg-for-the-Treatment-of-Wet-AMD.html">noted</a> in its letter to the company that the drug did not meet the primary efficacy endpoint in a study and recommended that confirmatory evidence of efficacy be submitted to support the application.CEO Bob Jahr said that the company is very disappointed with this outcome and intends to meet with the agency to receive additional clarity on requirements for approval.“It is important to also note that the CRL (letter) identified no other outstanding deficiencies in our BLA (application),” Jahr added.The company also said that it intends to continue its efforts to expand Lytenava into additional markets in Europe. It has already been granted Marketing Authorization by the European Commission in the European Union and Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for the treatment of wet AMD.OTLK is up by 26% this year but down by 68% over the past 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lisa-cook-to-sue-trump-administration-firing-her-federal-reserve-board/chsH6GARdjs">Lisa Cook To Sue Trump Administration For Firing Her From Federal Reserve Board: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Outlook Therapeutics Stock Nose-Dives 66% In Pre-Market – Here’s Why

The US FDA declined to approve the firm’s investigational drug Lytenava for the treatment of wet age-related macular degeneration, citing a lack of substantial evidence of effectiveness.

Medical device company enVVeno Medical Corporation (NVNO) on Wednesday announced that the U.S. Food &amp; Drug Administration (FDA) has refused to approve its application for its lead product, VenoValve, a surgical replacement venous valve for treating severe deep chronic venous insufficiency (CVI).Following the announcement, NVNO shares plunged 71% by Wednesday afternoon, at the time of writing.Severe deep chronic venous insufficiency (CVI) is a long-term condition where the veins in the legs have difficulty returning blood to the heart, leading to blood pooling and various symptoms like swelling, aching, and skin changes. This occurs primarily due to damaged or weakened valves within the deep leg veins.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVNO">NVNO</a> rose from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while retail chatter rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:563/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_20_at_12_41_02_PM_png_bca2208bb7.webp" alt="NVNO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Aug. 20, 2025 | Source: Stocktwits" width="563" height="61"><figcaption>NVNO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Aug. 20, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism for the company renegotiating with the FDA.<stembedurl>https://stocktwits.com/Flying_Trader2/message/625960642</stembedurl>Another user said that they see no value in the company with the VenoValve rejection.<stembedurl>https://stocktwits.com/kmx_swing/message/625941525</stembedurl>The FDA <a target="_blank" rel="noopener noreferrer nofollow" href="https://envveno.com/envveno-receives-not-approvable-letter-from-the-fda-for-the-venovalve/">said</a> in a letter that it completed its review of the company’s application for VenoValve but has decided that it is unable to approve it in its current form. The agency said that data generated by the company for the application was not sufficient on its own to determine the favorability of the benefit-risk profile for VenoValve.The FDA also raised concerns about bias and the possibility that clinical improvement occurred as a result of the patients being enrolled in a study. The agency further raised safety concerns, which were attributed to the VenoValve open surgical procedure, and which required re-hospitalizations.CEO Robert Berman said that the company is disappointed by the FDA’s decision and highlighted that a high percentage of patients in a study showed significant clinical improvement after receiving VenoValve. Berman added that the company will continue to work with the FDA on new criteria to demonstrate the safety and effectiveness of the device.The firm’s next steps may include a meeting with the FDA to discuss requirements for a potential resubmission of the VenoValve or appeal of the decision, along with appropriate next steps.NVNO stock is down by 59% this year and by about 77% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-says-tesla-model-yl-might-not-ever-come-to-us-markets/chsitLlRdhq">Elon Musk Said Tesla’s Model Y L Might Not Ever Come To US Markets – Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Medical Device Stock Just Plunged A Whopping 71% Today – Do You Own It?

enVVeno Medical Corporation CEO Robert Berman said that the company will continue to work with the FDA on new criteria to demonstrate the safety and effectiveness of its VenoValve device. 

Broadband provider WideOpenWest, Inc. (WOW) shares soared in Tuesday’s premarket session after the company announced a going-private transaction.The Engelwood, Colorado-based company said it has reached a definitive agreement under which affiliated investment funds of DigitalBridge and Crestview Partners will acquire all of its outstanding shares not already owned by Crestview and its affiliates.The deal has been negotiated for $5.20 per share in cash, with an enterprise value of about $1.5 billion.The per-share transaction value represented a 54% premium over WideOpenWest’s closing price on Monday.&nbsp;The company noted that the purchase price represented a 37.2% premium to the $3.79 stock price, before the initial non-binding offer of $4.80 submitted by the purchaser group on May 2, 2024.Reacting to the proposed transaction,&nbsp;<a href="https://stocktwits.com/symbol/WOW">WideOpenWest stock</a> jumped 46.63% to $5.On Stocktwits, retail sentiment toward the stock turned to ‘extremely bullish’ (94/100) by early Tuesday, from ‘neutral’ a day ago. The message volume on the stream perked up to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:623/46;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_12_at_5_14_45_AM_png_3d57ce659d.webp" alt="Screenshot 2025-08-12 at 5.14.45 AM.png" width="623" height="46"><figcaption>WOW sentiment and message volume as of 5:15 a.m. ET, Aug. 12 | source: Stocktwits</figcaption></figure>CEO Teresa Elder said,&nbsp; "WOW!'s next chapter with DigitalBridge and Crestview will bring new and exciting opportunities to our stakeholders and enhance our position as a trusted provider of fast, reliable, and affordable broadband solutions."Jonathan Friesel, Senior Managing Director and Head of Fiber at DigitalBridge, said, “We intend to invest in expanding and upgrading WOW!'s networks, adopting new technologies, and ensuring the organization has the resources and support needed to continue delivering fast, reliable internet service and a high-quality customer experience at competitive prices."WideOpenWest’s board has unanimously approved the proposed transaction. Crestview, whose holding represented 37% of WideOpenWest's outstanding shares, has agreed to vote in favor of the transaction, subject to specific terms and conditions set forth therein.The transaction is expected to close by the end of the year or in the first quarter of 2026, subject to the satisfaction of the closing conditions, including the receipt of stockholder approval and of required regulatory approvals.&nbsp;Upon completion of the transaction, WideOpenWest will no longer be traded or listed on any public securities exchange.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:<a href="https://stocktwits.com/news-articles/markets/equity/el-erian-says-us-china-tariff-truce-eliminates-risk-of-empty-shelves-for-christmas-but-won-t-solve-bigger-issues/chrDylBRd71"> El-Erian Says US-China Tariff Truce Eliminates Risk Of ‘Empty Shelves For Christmas’, But Won’t Solve Bigger Issues ‘Far Beyond Economics’</a>

WideOpenWest stock, WideOpenWest stock, WOW stock, WIOW stock price, why it’s moving, premarket jump

Why Shares Of Broadband Provider WideOpenWest Are Shooting Higher Premarket Today

The going-private deal has been negotiated for $5.20 per share in cash, with an enterprise value of about $1.5 billion.

BigBear.ai Holdings, Inc. (BBAI) shares tumbled in Monday’s extended trading after the artificial intelligence (AI)-powered decision intelligence solutions company announced an across-the-board miss for its second quarter.On Stocktwits, BigBear stock was the top-trending ticker by late Monday. The 24-hour message volume change on the stock’s stream leading up to late Monday was 1,872%.Retail sentiment toward the stock improved to ‘bullish’ (69/100) by late Monday from ‘neutral’ a day ago.<figure class="image"><img style="aspect-ratio:620/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_11_at_11_12_50_PM_png_d22c0e8760.webp" alt="Screenshot 2025-08-11 at 11.12.50 PM.png" width="620" height="63"><figcaption>BBAI sentiment and message volume as of 11:10 p.m. ET, Aug. 11 | source: Stocktwits</figcaption></figure>The McLean, Virginia-based company reported a loss of $0.71 per share for the second quarter of the fiscal year 2025, significantly wider than the year-ago loss of $0.06 per share. The Fiscal.ai-compiled called for a loss of $0.06 per share.Non-cash changes in derivative liabilities ($135.8 million) related to the changes in the fair value of the convertible features of the 2029 notes and warrants, and a non-cash goodwill impairment charge ($70.6 million) primarily weighed down on the bottom-line result.Quarterly revenue fell to $32.47 million from $39.78 million, missing the consensus of $40.58 million. The company attributed the lower revenue primarily to lower volume on certain army programs.The gross margin also contracted to 25% from 27.8%.&nbsp;CEO Kevin McAleenan said, “Our capital raising activities this quarter coincide with the tremendous opportunities we see coming from the One Big Beautiful Bill, particularly in the Department of Homeland Security, and several of which are uniquely aligned to our core capabilities.”BigBear guided 2025 revenue in the range of $125 million to $140 million, below the $167.74-million consensus estimate. The company withdrew its previously issued adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) guidance for the year, citing the uncertainty on certain Army programs as well as new anticipated growth investment spending in the second half of the year.Retailer users of the Stocktwits platform weren’t ready to give up yet on the stock. “Best time to buy is now,” said a bullish watcher.<stembedurl>https://stocktwits.com/astrix79/message/624708218</stembedurl>Another user expected a climb back soon after the steep drop.<stembedurl>https://stocktwits.com/astrix79/message/624707776</stembedurl>In overnight trading, BigBear stock was down over 30% at $4.90. If the losses are sustained in Tuesday’s regular session, the stock is on track to experience its worst day in more than a year, according to Koyfin data.The stock has gained approximately 60% for the year, excluding the after-hours decline.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/us-stock-futures-jittery-despite-us-chins-trade-truce-extension/chrDoS4Rder">US Stock Futures Jittery Despite US-China Trade Truce Extension: Strategist Says Tamer Inflation Print Key For Constructive Longer-Term Outlook</a>

In this photo illustration, a person holds a smartphone displaying the logo of BigBear.ai Holdings, Inc. (NYSE: BBAI), on August 8, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

BigBear Retail Traders Say ‘Time To Buy’ After Stock Craters Over 30% On Q2 Miss Amid Army Contract Scaleback

Quarterly revenue fell to $32.47 million from $39.78 million, missing the consensus of $40.58 million. 

Mullen Automotive, Inc. (MULN) announced on Thursday that its previously announced name change will take effect on July 28.The company will change its <a target="_blank" rel="noopener noreferrer nofollow" href="https://news.mullenusa.com/mullen-announces-company-name-change-to-bollinger-innovations-inc-effective-july-28-2025">name</a> to Bollinger Innovations, Inc. Its common stock will begin trading on The Nasdaq Capital Market under the new stock symbol BINI at market open on July 28.Mullen CEO David Michery said that the name change is aimed at bringing the company’s products and brands together under one unified identity. Bollinger is the name of Mullen’s majority-owned EV truck company.The name and stock symbol change does not affect the company’s legal structure or business operations, it said, adding that stockholders need not take any action regarding the changes.MULN stock is trading 14% lower at the time of writing on Thursday afternoon.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MULN">Mullen</a> fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours while message volume stayed at ‘high’ levels. According to Stocktwits data, retail chatter around Mullen has increased 35% over the past 24 hours.<figure class="image"><img style="aspect-ratio:1336/122;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_24_at_1_15_36_PM_png_be73fc102e.webp" alt="MULN's Sentiment Meter and Message Volume as of 1:15 p.m. ET on July 24, 2025 | Source: Stocktwits" width="1336" height="122"><figcaption>MULN's Sentiment Meter and Message Volume as of 1:15 p.m. ET on July 24, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the company might have a plan behind the name change.<stembedurl>https://stocktwits.com/ItsMeToo/message/622296000</stembedurl>Southern California-based Mullen builds commercial electric vehicles. Its commercial EV lineup includes the Mullen ONE, a cargo van, and the Mullen THREE, a cab chassis truck. It's majority-owned EV truck company, Bollinger Motors, makes the Bollinger B4 electric truck.In June, the company announced that it had raised its stake in Bollinger Motors by acquiring an additional 21% of the company, thereby increasing its total ownership to 95%. This acquisition followed the company's resolution of claims and debt that had led to a court-ordered receivership for Bollinger.MULN stock has wiped nearly all of its value over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/novavax-announces-positive-preclinical-data-from-bird-flu-vaccine/ch8zRUiR5Ht">Novavax Announces Positive Preclinical Data From Bird Flu Vaccine: Retail Wonders When Will The Stock Be Fairly Valued</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Mullen Automotive logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Mullen Automotive Name Change To Be Effective July 28, But Retail’s Not Optimistic Yet

Mullen Automotive will change its name to Bollinger Innovations, Inc. 

Veritone Inc. (NASDAQ: VERI), a company that builds AI tools for businesses, has earned “Awardable” status from the Department of Defense’s Platform One Marketplace on Thursday, opening the door to broader use of its technology across U.S. military agencies.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/VERI">Veritone stock&nbsp;</a>jumped over 10% on Thursday morning.This recognition enables Veritone to provide its AI-powered products directly to U.S. defense agencies through a simplified purchasing system called Platform One (P1) Marketplace.&nbsp;On Stocktwits, retail sentiment toward Veritone jumped to ‘extremely bullish’(81/100) from ‘neutral’ the previous day. Message volume levels surged as well, shifting to ‘extremely high’(76/100) from ‘normal’ in 24 hours.&nbsp;<figure class="image"><img style="aspect-ratio:963/110;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_17_104653_png_3be5e73caa.webp" alt="VERI’s Sentiment Meter and Message Volume as of 10:45 a.m. ET on July 17, 2025 | Source: Stocktwits" width="963" height="110"><figcaption>VERI’s Sentiment Meter and Message Volume as of 10:45 a.m. ET on July 17, 2025 | Source: Stocktwits</figcaption></figure>The stock experienced an over 800% hike in message count from Stocktwits users in the last 24 hours.&nbsp;The P1 Marketplace acts as a central platform where pre-approved technologies are available for quick and efficient contracting.With this new status, defense agencies can more easily obtain Veritone’s advanced software for processing unstructured data, such as audio and video files.&nbsp;This could help speed up decision-making, investigations, and operational assessments. Solutions like Veritone Track, Redact, Investigate, and aiWARE are designed to extract insights from complex media content, helping agencies respond more quickly and efficiently.“Our suite of technologies, including Track, Redact, Investigate, and aiWARE – all part of our iDEMS suite – represents a comprehensive approach to solving critical data management and analysis needs, enabling agencies to work smarter, faster, and more securely,” said Chiarman, President and CEO, Ryan Steelberg.The company’s inclusion in the P1 Marketplace, following its earlier recognition on the Tradewinds Solutions Marketplace, reflects its growing role in government digital transformation.&nbsp;According to Veritone, the platform will reduce procurement timelines and facilitate faster innovation delivery to defense teams on the ground.Veritone stock has gained over 46% in the past months but has lost over 33% so far in 2025.A bullish stocktwits user said the stock is undervalued.<stembedurl>https://stocktwits.com/FrostyMeltDown/message/621171757</stembedurl>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/roblox-sees-explosion-in-retail-chatter-as-new-features-put-teens-in-control/ch8KmZlR5YC">Roblox Sees Explosion In Retail Chatter As New Features Put Teens in Control, Parents In The Loop</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Pentagon logo is seen ahead of a press conference at the Pentagon in Washington D.C., United States on October 17, 2023.

Veritone’s AI Solutions Land Spot On DoD’s Elite Procurement List: Retail Chatter Explodes 800% In 24 Hours

The recognition enables Veritone to provide its AI-powered products directly to U.S. defense agencies through a simplified purchasing system called P1 Marketplace. 

CEL-SCI Corporation (CVM) on Friday announced it has reached an agreement with one of Saudi Arabia’s premier pharmaceutical companies for a partnership that spans regulatory and commercial activities for Multikine in the Kingdom of Saudi Arabia.<a href="https://stocktwits.com/symbol/CVM">CEL-SCI</a>’s shares were trading 33% higher at the time of writing.The formal agreement is expected to be signed with the Saudi pharmaceutical partner in the coming weeks, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250711051288/en/CEL-SCI-to-Sign-Partnership-Agreement-With-Leading-Saudi-Arabian-Pharma-Company-for-Multikine-in-the-Treatment-of-Head-Neck-Cancer">said</a>. The partner will then file a Breakthrough Medicine Designation application for Multikine with the Saudi Food and Drug Authority (SFDA).Multikine is a cancer drug administered before surgery as a treatment for newly diagnosed and previously untreated head and neck cancer.If granted Breakthrough Medicine Designation, Multikine would immediately become available for patient access, reimbursement, or sale in Saudi Arabia. CEL-SCI said that it believes Multikine meets all requirements for Breakthrough Medicine Designation as published by the SFDA and is now developing a comprehensive commercialization plan with its Saudi pharma partner.In a study spanning 20 countries, Multikine increased the 5-year survival rate of the target patient population to 73% versus 45% in patients treated with standard of care alone. The 5-year risk of death was halved from 55% to 27%.The drug, given right after diagnosis and before surgery, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.CEL-SCI also said on Friday that several Saudi funds have expressed interest in investing in Multikine, CEL-SCI, and/or a potential joint venture to serve the wider Middle East and North Africa (MENA) market.On Stocktwits, retail sentiment around CVM jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:625/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_11_at_11_59_25_AM_png_2f84b0779d.webp" alt="CVM's Sentiment Meter and Message Volume as of 12 p.m. ET on July 11, 2025 | Source: Stocktwits" width="625" height="63"><figcaption>CVM's Sentiment Meter and Message Volume as of 12 p.m. ET on July 11, 2025 | Source: Stocktwits</figcaption></figure>CVM stock is down by 58% this year and by over 86% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/meta-reportedly-stands-firm-on-eu-ad-model/ch8cirOR5Zw">Meta Reportedly Stands Firm On EU Ad Model Amid Looming Regulatory Penalties</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CEL-SCI Stock Soars On Imminent Partnership With Saudi Arabian Pharma Company For Cancer Drug: Retail’s Thrilled

The formal agreement is expected to be signed with the Saudi pharmaceutical partner in the coming weeks, CEL-SCI said.

IWC
iShares Micro-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWC News

IWC iShares Micro-Cap ETF